[{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"ISLA101","moa":"Chloroquine target","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Island Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Island Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Island Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"Beyond Drug Development","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Fenretinide","moa":"retinol derivatives","graph1":"Undisclosed","graph2":"Phase I","graph3":"Island Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Island Pharmaceuticals \/ Beyond Drug Development","highestDevelopmentStatusID":"6","companyTruncated":"Island Pharmaceuticals \/ Beyond Drug Development"},{"orgOrder":0,"company":"Island Pharmaceuticals","sponsor":"State University of New York","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"ISLA-101","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Island Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Island Pharmaceuticals \/ State University of New York","highestDevelopmentStatusID":"8","companyTruncated":"Island Pharmaceuticals \/ State University of New York"}]

Find Clinical Drug Pipeline Developments & Deals by Island Pharmaceuticals

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : ISLA101 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dengue.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          July 30, 2024

                          Lead Product(s) : ISLA101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : Fenretinide is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 26, 2023

                          Lead Product(s) : Fenretinide

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Beyond Drug Development

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Formnext Forum
                          Not Confirmed
                          Formnext Forum
                          Not Confirmed

                          Details : ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 19, 2021

                          Lead Product(s) : ISLA-101

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : State University of New York

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank